Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Generation Bio Co.

Get SEC filing alerts via email and in your feed for Generation Bio Co.

GBIO

Generation Bio Co.

About Generation Bio Co.

Generation Bio is a biotechnology company focused on developing targeted, reprogrammable therapeutics for T cell-driven autoimmune diseases. Utilizing proprietary lipid nanoparticle delivery systems and siRNA technology, it aims to precisely silence disease-causing genes within T cells. The company’s approach offers potential for high specificity, safety, and access to previously undruggable targets, with a focus on innovative gene silencing and collaboration in immunology and genetic medicine.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Generation Bio Co.

1
1
Generation Bio Co. Generation Bio Reports Significant Revenue Decline and Strategic Restructuring in Q3 2025

Via official filing (AI summary) | 8 months ago | 0 comments

2
1
Generation Bio Co. Generation Bio Reports 81% Decline in Collaboration Revenue and $20.9 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Generation Bio Co. Generation Bio Reports $8.7M Collaboration Revenue and $14.8M Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Generation Bio Co. Generation Bio Reports Mixed Financial Results, Decrease in Cash and Cash Equivalents in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments